214 related articles for article (PubMed ID: 36949199)
1. RHOJ controls EMT-associated resistance to chemotherapy.
Debaugnies M; Rodríguez-Acebes S; Blondeau J; Parent MA; Zocco M; Song Y; de Maertelaer V; Moers V; Latil M; Dubois C; Coulonval K; Impens F; Van Haver D; Dufour S; Uemura A; Sotiropoulou PA; Méndez J; Blanpain C
Nature; 2023 Apr; 616(7955):168-175. PubMed ID: 36949199
[TBL] [Abstract][Full Text] [Related]
2. RHOJ Induces Epithelial-to-Mesenchymal Transition by IL-6/STAT3 to Promote Invasion and Metastasis in Gastric Cancer.
Ma Z; Sun Q; Zhang C; Zheng Q; Liu Y; Xu H; He Y; Yao C; Chen J; Xia H
Int J Biol Sci; 2023; 19(14):4411-4426. PubMed ID: 37781036
[No Abstract] [Full Text] [Related]
3. Repression of RhoJ expression promotes TGF-β-mediated EMT in human non-small-cell lung cancer A549cells.
Nozaki M; Nishizuka M
Biochem Biophys Res Commun; 2021 Aug; 566():94-100. PubMed ID: 34119829
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological targeting of netrin-1 inhibits EMT in cancer.
Lengrand J; Pastushenko I; Vanuytven S; Song Y; Venet D; Sarate RM; Bellina M; Moers V; Boinet A; Sifrim A; Rama N; Ducarouge B; Van Herck J; Dubois C; Scozzaro S; Lemaire S; Gieskes S; Bonni S; Collin A; Braissand N; Allard J; Zindy E; Decaestecker C; Sotiriou C; Salmon I; Mehlen P; Voet T; Bernet A; Blanpain C
Nature; 2023 Aug; 620(7973):402-408. PubMed ID: 37532929
[TBL] [Abstract][Full Text] [Related]
5. RhoJ modulates melanoma invasion by altering actin cytoskeletal dynamics.
Ho H; Soto Hopkin A; Kapadia R; Vasudeva P; Schilling J; Ganesan AK
Pigment Cell Melanoma Res; 2013 Mar; 26(2):218-25. PubMed ID: 23253891
[TBL] [Abstract][Full Text] [Related]
6. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.
Sun L; Yao Y; Liu B; Lin Z; Lin L; Yang M; Zhang W; Chen W; Pan C; Liu Q; Song E; Li J
Oncogene; 2012 Jan; 31(4):432-45. PubMed ID: 21725369
[TBL] [Abstract][Full Text] [Related]
7. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis.
Pastushenko I; Mauri F; Song Y; de Cock F; Meeusen B; Swedlund B; Impens F; Van Haver D; Opitz M; Thery M; Bareche Y; Lapouge G; Vermeersch M; Van Eycke YR; Balsat C; Decaestecker C; Sokolow Y; Hassid S; Perez-Bustillo A; Agreda-Moreno B; Rios-Buceta L; Jaen P; Redondo P; Sieira-Gil R; Millan-Cayetano JF; Sanmatrtin O; D'Haene N; Moers V; Rozzi M; Blondeau J; Lemaire S; Scozzaro S; Janssens V; De Troya M; Dubois C; Pérez-Morga D; Salmon I; Sotiriou C; Helmbacher F; Blanpain C
Nature; 2021 Jan; 589(7842):448-455. PubMed ID: 33328637
[TBL] [Abstract][Full Text] [Related]
8. Loss of TAK1 increases cell traction force in a ROS-dependent manner to drive epithelial-mesenchymal transition of cancer cells.
Lam CR; Tan C; Teo Z; Tay CY; Phua T; Wu YL; Cai PQ; Tan LP; Chen X; Zhu P; Tan NS
Cell Death Dis; 2013 Oct; 4(10):e848. PubMed ID: 24113182
[TBL] [Abstract][Full Text] [Related]
9. RhoJ promotes hypoxia induced endothelial-to-mesenchymal transition by activating WDR5 expression.
Liu L; Chen J; Sun L; Xu Y
J Cell Biochem; 2018 Apr; 119(4):3384-3393. PubMed ID: 29130522
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
11. Low mitochondrial DNA copy number induces chemotherapy resistance via epithelial-mesenchymal transition by DNA methylation in esophageal squamous cancer cells.
Kubo Y; Tanaka K; Masuike Y; Takahashi T; Yamashita K; Makino T; Saito T; Yamamoto K; Tsujimoto T; Harino T; Kurokawa Y; Yamasaki M; Nakajima K; Eguchi H; Doki Y
J Transl Med; 2022 Aug; 20(1):383. PubMed ID: 36038893
[TBL] [Abstract][Full Text] [Related]
12. Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma.
Cheng CW; Hsiao JR; Fan CC; Lo YK; Tzen CY; Wu LW; Fang WY; Cheng AJ; Chen CH; Chang IS; Jiang SS; Chang JY; Lee AY
Mol Carcinog; 2016 May; 55(5):499-513. PubMed ID: 25728212
[TBL] [Abstract][Full Text] [Related]
13. RhoJ interacts with the GIT-PIX complex and regulates focal adhesion disassembly.
Wilson E; Leszczynska K; Poulter NS; Edelmann F; Salisbury VA; Noy PJ; Bacon A; Rappoport JZ; Heath JK; Bicknell R; Heath VL
J Cell Sci; 2014 Jul; 127(Pt 14):3039-51. PubMed ID: 24928894
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
15. RhoC upregulation is correlated with reduced E-cadherin in human breast cancer specimens after chemotherapy and in human breast cancer MCF-7 cells.
Kawata H; Kamiakito T; Omoto Y; Miyazaki C; Hozumi Y; Tanaka A
Horm Cancer; 2014 Dec; 5(6):414-23. PubMed ID: 25123151
[TBL] [Abstract][Full Text] [Related]
16. Bovine lactoferrin reverses programming of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition in oral squamous cell carcinoma.
Chea C; Miyauchi M; Inubushi T; Okamoto K; Haing S; Nguyen PT; Imanaka H; Takata T
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):142-147. PubMed ID: 30415774
[TBL] [Abstract][Full Text] [Related]
17. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
[TBL] [Abstract][Full Text] [Related]
18. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis on the whole Rho-GAP family reveals that ARHGAP4 suppresses EMT in epithelial cells under negative regulation by Septin9.
Kang N; Matsui TS; Liu S; Fujiwara S; Deguchi S
FASEB J; 2020 Jun; 34(6):8326-8340. PubMed ID: 32378260
[TBL] [Abstract][Full Text] [Related]
20. Towards Understanding the Development of Breast Cancer: The Role of RhoJ in the Obesity Microenvironment.
Bou Malhab LJ; Nair VA; Qaisar R; Pintus G; Abdel-Rahman WM
Cells; 2024 Jan; 13(2):. PubMed ID: 38247865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
